Cantharidin induces G2/M arrest and triggers apoptosis in renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Renal cell carcinoma (RCC) is a significant health concern.
• Understanding the molecular mechanisms underlying RCC progression is crucial for developing effective treatments.
• Notch signaling pathway components, Notch1 and Jagged1, are implicated in various cancers.

Purpose of the Study:

• To investigate the effects of cantharidin on renal cancer cell lines (ACHN and Caki-1).
• To evaluate cantharidin's impact on cell cycle distribution, apoptosis induction, and Notch1/Jagged1 expression.
• To assess the therapeutic potential of cantharidin in renal cancer.

Main Methods:

• Cell viability assays were performed on ACHN and Caki-1 cells.
• Flow cytometry and cell cycle analysis were used to assess cell cycle distribution.
• Western blot analysis and immunohistochemistry were employed to detect protein expression.
• The study utilized ACHN and Caki-1 renal cancer cell lines and human RCC tissues.

Main Results:

• Cantharidin demonstrated dose- and time-dependent inhibition of cell viability in ACHN and Caki-1 cells.
• Treatment with cantharidin induced significant G2/M phase cell cycle arrest.
• Cantharidin markedly increased the proportion of apoptotic cells in both cell lines.
• Cantharidin inhibited the expression of Notch1 and Jagged1 in renal cancer cells.

Conclusions:

• Cantharidin exhibits potent anti-cancer effects against renal cancer cells.
• The mechanism involves inducing apoptosis and G2/M cell cycle arrest.
• Cantharidin's inhibitory effect on Notch1 and Jagged1 suggests a role in its anti-cancer activity.
• Cantharidin holds promise as a therapeutic agent for renal cancer treatment.